Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications.
about
Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiologyAntibodies for biodefenseSpecific egg yolk immunoglobulin as a new preventive approach for Shiga-toxin-mediated diseasesIntracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody.Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coliBiodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice.A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome.Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2.Selective Evolution of Ligands by Exponential Enrichment to Identify RNA Aptamers against Shiga Toxins.Evaluation of Fab and F(ab')2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2.Pathogenesis of Escherichia coli O157:H7 strain 86-24 following oral infection of BALB/c mice with an intact commensal flora.Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli.Testing the efficacy and toxicity of adenylyl cyclase inhibitors against enteric pathogens using in vitro and in vivo models of infection.Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7.Shiga toxin-producing Escherichia coli in swine: the public health perspectiveMouse models of Escherichia coli O157:H7 infection and shiga toxin injectionTargeting virulence not viability in the search for future antibacterials.Development and characterization of recombinant antibody fragments that recognize and neutralize in vitro Stx2 toxin from Shiga toxin-producing Escherichia coli.Nitric oxide inhibits Shiga-toxin synthesis by enterohemorrhagic Escherichia coliInteraction between Shiga toxin and monoclonal antibodies: binding characteristics and in vitro neutralizing abilities.Pathogenesis of renal disease due to enterohemorrhagic Escherichia coli in germ-free miceMutation of the Enterohemorrhagic Escherichia coli Core LPS Biosynthesis Enzyme RfaD Confers Hypersusceptibility to Host Intestinal Innate Immunity In vivoUpdate on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations.Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model.Targeting pili in enterococcal pathogenesis.Targeting bacterial toxins.Bile salts induce resistance to polymyxin in enterohemorrhagic Escherichia coli O157:H7.Shiga toxin 2-specific but not shiga toxin 1-specific human monoclonal antibody protects piglets challenged with enterohemorrhagic Escherichia coli producing shiga toxin 1 and shiga toxin 2.Shiga Toxin Therapeutics: Beyond Neutralization.Modeling neutralization of Shiga 2 toxin by A-and B-subunit-specific human monoclonal antibodies.Global effects of the cell-to-cell signaling molecules autoinducer-2, autoinducer-3, and epinephrine in a luxS mutant of enterohemorrhagic Escherichia coli.Rapid detection of Shiga toxin-producing Escherichia coli by optical immunoassay.
P2860
Q27025422-931BB303-E2F4-4097-B19C-570A55D0CD25Q28394941-7D7271D1-8F02-4E35-852A-84E3F5735090Q28743696-D86127A7-8344-472F-8256-6A6382B3595AQ30481790-8B77E760-02AB-4420-8B4A-7E74C79D40E1Q33388849-53BCEF44-224C-4D93-9B26-089B873CB574Q33401560-2B87BEC4-0EB5-4A40-940D-53116A279A5DQ33410645-1AB62687-DD3E-44D2-84DE-CFA28F139AFAQ33415691-2D42283B-C130-4676-A527-AD2DED4B360EQ33418526-F4FEEB7F-47A8-4B32-B8C2-B702BA473738Q33545441-0665363F-D902-4116-90CC-F63EE8F2BC88Q33563140-B8D6BE64-8DB3-4CAF-AA00-DE521FCB15FAQ33675818-16E68BB1-CDBF-4D02-928F-A49E10E8AD81Q33712512-F059CF14-BA3C-4D22-8688-02D60AACA691Q33768681-550725AE-BB6D-4779-BDE2-E463CD3982CFQ33769026-C7C3D922-5C68-45C9-8F1A-DE26236D5B9CQ33965188-A3352F90-DFE4-4679-9E15-AB2DF9B20AE4Q34000479-47ED32FC-6A79-4FD3-8B49-FA1FF97E2014Q34497115-FF1B155A-1E1B-4350-A329-BC9C501B17A0Q35023691-D44672D9-7CC0-4AF2-9E92-B5D7B31717E1Q35581606-59E4B957-BFF1-417D-89C1-129C83169104Q35840558-2DB17165-646E-4529-BD94-2D37B9012297Q36329665-44F3C68E-F4D4-4F82-B4C6-E7BD79B8CD64Q36747071-F62DA7AF-1678-4597-B9C4-6657FDC3E4C2Q37170303-95CF90BB-1212-44B2-9CDE-35513E8965C3Q37322141-85C6BC9B-5FBB-430F-B0E1-0F503FBD717AQ37672981-022E16F1-7987-48CE-8CE7-C7D5BCCDEAE1Q37713275-B0577A11-6CC9-48F7-B5BB-E3ADDD42F7DBQ37996325-91D565CA-EB33-472F-A5A3-0D8EB428E0B4Q38284259-E4A52BB5-6699-48C2-BD15-C24FAACCCBFAQ39821928-782AF59D-0115-4171-83DF-21828D148D71Q41669177-E02A1D92-DC01-4537-8401-D8A45D9EDC9EQ41994849-A6AB6812-8D4A-4524-8699-FB4279FB2D67Q42634023-9BDEDD37-359A-46DD-B124-34EA722A24FBQ42637879-0EFF7C8F-E4C5-41A1-A1E4-308C93D60AF9
P2860
Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Human antibody against shiga t ...... fatal systemic complications.
@ast
Human antibody against shiga t ...... fatal systemic complications.
@en
type
label
Human antibody against shiga t ...... fatal systemic complications.
@ast
Human antibody against shiga t ...... fatal systemic complications.
@en
prefLabel
Human antibody against shiga t ...... fatal systemic complications.
@ast
Human antibody against shiga t ...... fatal systemic complications.
@en
P2093
P2860
P1476
Human antibody against shiga t ...... fatal systemic complications.
@en
P2093
Abhineet S Sheoran
Arthur Donohue-Rolfe
Barrett R Harvey
George Georgiou
Jean Mukherjee
Susan Chapman-Bonofiglio
P2860
P304
P356
10.1128/IAI.73.8.4607-4613.2005
P407
P50
P577
2005-08-01T00:00:00Z